News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) to Present at ISBioTech Annual Meeting



3/11/2013 9:36:44 AM

SYDNEY, AUSTRALIA--(Marketwire - March 10, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") announces that its Vice President of Manufacturing, Marta Schilling, will present at the 3rd annual meeting of the International Society for BioProcess Technology (ISBioTech) to be held in Rosslyn, Virginia.

"The Challenges of Harmonizing cGMP Manufacturing Across Multiple CMOs on Different Continents" will be delivered at 10:30am (local time) on March 13, 2013. Ms. Schilling will present on the challenges of harmonizing manufacturing for personalized immunocellular products in multiple facilities in different regions. She will also review Prima's accomplishments in the successful implementation of harmonized manufacturing among the Company's three CVac manufacturing facilities in Australia, the USA, and Germany.

Ms. Schilling: "I am pleased to have been given the opportunity to present at the ISBioTech conference. There is significant industry interest in Prima's operational, logistical, and technical accomplishments to support the consistent global manufacture of a product like CVac."

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.


For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES